scholarly journals Phase 1 Study of Edasalonexent (CAT-1004), an Oral NF-κB Inhibitor, in Pediatric Patients with Duchenne Muscular Dystrophy

2019 ◽  
Vol 6 (1) ◽  
pp. 43-54 ◽  
Author(s):  
Erika Finanger ◽  
Krista Vandenborne ◽  
Richard S. Finkel ◽  
H. Lee Sweeney ◽  
Gihan Tennekoon ◽  
...  
Keyword(s):  
Duchenne Muscular Dystrophy ◽  
Muscular Dystrophy ◽  
Pediatric Patients ◽  
Phase 1 ◽  
Phase 1 Study

scholarly journals PDCT-06. PHASE 1 STUDY OF ONC201 IN PEDIATRIC PATIENTS WITH H3 K27M-MUTANT HIGH GRADE GLIOMA OR NEWLY DIAGNOSED DIPG

2018 ◽  
Vol 20 (suppl_6) ◽  
pp. vi201-vi201
Author(s):  
Sharon Gardner ◽  
Fernando Suarez ◽  
James M Stafford ◽  
Rohinton S. Tarapore ◽  
Krystal Merdinger ◽  
...  
Keyword(s):  
Pediatric Patients ◽  
Phase 1 ◽  
High Grade Glioma ◽  
High Grade ◽  
Newly Diagnosed ◽  
Phase 1 Study

Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 10052-10052 ◽  
Author(s):  
Holly Jane Meany ◽  
Jeffrey Dome ◽  
Pamela S. Hinds ◽  
Rochelle Bagatell ◽  
Suzanne Shusterman ◽  
...  
Keyword(s):  
Solid Tumors ◽  
Pediatric Patients ◽  
Phase 1 ◽  
Phase 1 Study

scholarly journals Phase 1 Study of Valproic Acid in Pediatric Patients with Refractory Solid or CNS Tumors: A Children's Oncology Group Report

2010 ◽  
Vol 17 (3) ◽  
pp. 589-597 ◽  
Author(s):  
Jack M. Su ◽  
Xiao-Nan Li ◽  
Patrick Thompson ◽  
Ching-Nan Ou ◽  
Ashish M. Ingle ◽  
...  
Keyword(s):  
Valproic Acid ◽  
Pediatric Patients ◽  
Phase 1 ◽  
Cns Tumors ◽  
Oncology Group ◽  
Phase 1 Study ◽  
Group Report

A Phase 1 Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 7 Days Every 21 Days in Pediatric Patients with Solid Tumors

2006 ◽  
Vol 12 (16) ◽  
pp. 4882-4887 ◽  
Author(s):  
Elizabeth Fox ◽  
John M. Maris ◽  
Brigitte C. Widemann ◽  
Kysa Meek ◽  
Anne Goodwin ◽  
...  
Keyword(s):  
Solid Tumors ◽  
Pediatric Patients ◽  
Phase 1 ◽  
Phase 1 Study ◽  
Tubulin Inhibitor ◽  
Orally Bioavailable

A Phase 1 Study of Combotox in Pediatric Patients With Refractory B-lineage Acute Lymphoblastic Leukemia

2009 ◽  
Vol 31 (12) ◽  
pp. 936-941 ◽  
Author(s):  
Larry Herrera ◽  
Bruce Bostrom ◽  
Lisa Gore ◽  
Eric Sandler ◽  
Glen Lew ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Pediatric Patients ◽  
Lymphoblastic Leukemia ◽  
Phase 1 ◽  
Phase 1 Study ◽  
B Lineage

scholarly journals Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors

Cancer ◽  
2009 ◽  
Vol 115 (8) ◽  
pp. 1765-1775 ◽  
Author(s):  
Lisa M. McGregor ◽  
Sheri L. Spunt ◽  
Wayne L. Furman ◽  
Clinton F. Stewart ◽  
Paula Schaiquevich ◽  
...  
Keyword(s):  
Solid Tumors ◽  
Pediatric Patients ◽  
Phase 1 ◽  
Phase 1 Study

scholarly journals Phase 1 study of an oxaliplatin and etoposide regimen in pediatric patients with recurrent solid tumors

Cancer ◽  
2009 ◽  
Vol 115 (3) ◽  
pp. 655-664 ◽  
Author(s):  
Lisa M. McGregor ◽  
Sheri L. Spunt ◽  
Victor M. Santana ◽  
Clinton F. Stewart ◽  
Deborah A. Ward ◽  
...  
Keyword(s):  
Solid Tumors ◽  
Pediatric Patients ◽  
Phase 1 ◽  
Phase 1 Study

CAT-1004, an oral agent targeting NF-κB in development for treatment of Duchenne muscular dystrophy: Phase 1/2 study design

2015 ◽  
Vol 25 ◽  
pp. S262 ◽  
Author(s):  
J. Donovan ◽  
H. Sweeney ◽  
K. Vandenborne ◽  
B. Russman ◽  
M. Jirousek ◽  
...  
Keyword(s):  
Duchenne Muscular Dystrophy ◽  
Muscular Dystrophy ◽  
Study Design ◽  
Phase 1 ◽  
Oral Agent
Sign in / Sign up

Export Citation Format

Share Document